A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C; HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms ALLY-2
- Sponsors Bristol-Myers Squibb
- 07 Sep 2016 Results analyzing HCV GT2 NS5A sequencing data from five clinical trials and one database (The Los Alamos hepatitis C sequence database) (n=426) published in the Journal of Antimicrobial Chemotherapy.
- 29 Mar 2016 Results (n=151) published in the Clinical Infectious Diseases
- 25 Feb 2016 Interim results (n=13) of NS5A & NS5B minor variant analyses presented at the 23rd Conference on Retroviruses and Opportunistic Infections.